You are here

Loxo Oncology

Lilly, with Alzheimer's in its crosshairs, forms new neuroscience unit, unifies oncology under Loxo exec

Fierce Biotech

Tue, 08/17/21 - 10:26 am

Alzheimer's disease

Lilly cancer R&D chief Bilenker quits, handing reins to deputy

Fierce Biotech

Tue, 02/2/21 - 11:09 pm

ASH 2020 – UK biotech's hollow victory

EP Vantage

Mon, 12/7/20 - 10:34 am

#ASH20: Loxo and Eli Lilly show off PhI/II data for their BTK inhibitor in mantle cell lymphoma

Endpoints

Sat, 12/5/20 - 11:28 pm

clinical trials

mantle cell lymphoma

non-Hodgkin lymphoma

A groundbreaking cancer drug nabs fast OK, giving Eli Lilly boasting rights as a rival speeds close behind

Endpoints

Sun, 05/10/20 - 09:30 pm

Blueprint Medicines

ASH: Eli Lilly plots 'ambitious' cancer program after sharing early BTK data

Fierce Biotech

Sun, 12/8/19 - 10:20 pm

Lilly puts its cancer future in Loxo's hands

Biopharma Dive

Thu, 12/5/19 - 10:20 am

Lilly's RET drug, nabbed in Loxo buyout, hits 68% ORR in lung cancer

Fierce Biotech

Mon, 09/9/19 - 10:21 am

non-small cell lung cancer

Bayer posts early clinical data on follow-up to Loxo’s Vitrakvi

Fierce Biotech

Mon, 04/1/19 - 09:37 pm

Bayer acquires full Vitrakvi rights from Eli Lilly's Loxo

Yahoo/Reuters

Fri, 02/15/19 - 10:27 am

Eli Lilly Misses Q4 Earnings, Cuts 2019 Outlook After Loxo Oncology Deal

TheStreet.com

Wed, 02/6/19 - 09:47 am

Eli Lilly Loxo Oncology Transaction Clears A Hurdle

CP Wire

Fri, 02/1/19 - 09:48 am

Eli Lilly Loxo Oncology Transaction Clears A Hurdle

Fri, 02/1/19 - 09:43 am

A flashy 2019 start to pharma M&A, but will it last?

Biopharma Dive

Tue, 01/22/19 - 11:55 pm

Bristol-Myers Squibb

No bidding war for Loxo, so did Lilly overpay? Don’t rush to judgment, analysts say

Fierce Pharma

Fri, 01/18/19 - 10:27 am

Looking to make a splash at JPMorgan, Eli Lilly rushed to put its $8B buyout deal together for Loxo in 10 days

Endpoints

Thu, 01/17/19 - 11:10 am

Lilly eyes more cancer deals, but wary of CAR-T, gene therapy

Yahoo/Reuters

Sat, 01/12/19 - 08:49 pm

The winners and losers from JPM 2019

Biopharma Dive

Fri, 01/11/19 - 11:51 am

SAGE Therapeutics

The 3 Best-Performing Biotech Stocks at the J.P. Morgan Healthcare Conference

Motley Fool

Fri, 01/11/19 - 09:59 am

SAGE Therapeutics

Does Eli Lilly's $8 Billion Splurge Make Array BioPharma a Buy Now?

Motley Fool

Wed, 01/9/19 - 09:43 am

Array Biopharma

Pages